Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Somavert (pegvisomant) - Important Safety Information from Pfizer as approved by the Irish Medicines Board
Notice type:
3rd Party Publications
Date:
03/04/2012
Problem Or Issue:
Important Safety Information communication from Pfizer informing Somavert prescribers that an improved drug substance manufacturing process which improves the quality profile of the B2036 protein (pegvisomant) is now in place.
Somavert (pegvisomant) - Important Safety Information from Pfizer as approved by the Irish Medicines Board
« Back
Date Printed: 06/05/2024